TITLE

Therapy explosion

AUTHOR(S)
SCHWANKE, JANE
PUB. DATE
August 2005
SOURCE
Dermatology Times;Aug2005, Vol. 26 Issue 8, p28
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article suggests various therapies used in the treatment of psoriasis. The various procedures used includes T-cell drugs Raptiva(efalizumab, Biogen), the best therpy for treating psoriasis, granuloma annulare, lichenplanus, alopecia areata and atopic dermatitis. The article also discourses the application of Riluxan (rituximab,IDEC) in the treatment of lymphoma, B-cell lymphoma of the skin, pemphigus, dermatomyositis and lupus.
ACCESSION #
23315235

 

Related Articles

  • Novel applications of Rituximab in dermatological disorders. Bhandari, Prasan R.; Pai, Varadraj V. // Indian Dermatology Online Journal;Jul-Sep2014, Vol. 5 Issue 3, p250 

    Rituximab is a monoclonal therapeutic anti-CD20 antibody that has been approved for use in lymphoma and rheumatoid arthritis. Over the past decade several reports based on case series and observational studies have recorded the benefits of rituximab in particular groups of dermatological...

  • DERMATOLOGICAL DISORDERS.  // Monthly Prescribing Reference;Feb2011, Vol. 27 Issue 2, p122 

    A part of the book "Monthly Prescribing Reference" for February 2011 is presented. It offers an overview of pharmacological treatments for dermatological disorders including acne, psoriasis and skin infections. The drugs include Aczone from Allergan, Neoral from Novartis and Abreva from...

  • Can-Fite: therapeutic approach bolstered by positive results in psoriasis trial.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p18 

    The article reports on the positive outcome of the psoriasis trial of Israel-based biopharmaceutical firm Can-Fite Biopharma Ltd. The 75-patient Phase II double-blind clinical study of the anti-TNF drug CF101 in patients with moderate to severe psoriasis resulted to efficacy upon oral...

  • R-CHOP plus radiation improved outcomes in bulky B-cell lymphoma.  // Hem/Onc Today;4/25/2014, Vol. 15 Issue 8, p31 

    The article discusses the study that found improved outcomes among patients with aggressive, bulky B-cell lymphoma with addition of radiation therapy to rituximab plus cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (R-CHOP).

  • Maintenance rituximab extended PFS in follicular lymphoma. Todak, Alexandra // Hem/Onc Today;5/25/2014, Vol. 15 Issue 10, p36 

    The article discusses research being done on the extended progression-free survival demonstrated by patients with follicular lymphoma who achieved stable disease with rituximab-based induction therapy, which references a study by L. J. Nastoupil et al. published in a 2014 issue of "Cancer."

  • Targeted cancer therapies struggle in Mexico and Brazil.  // PharmacoEconomics & Outcomes News;Jun2014, Vol. 705 Issue 1, p11 

    The article reports on 2014 findings in Mexico and Brazil which showed the incomplete coverage of targeted cancer therapies like rituximab (MabThera) for non-Hodgkin's lymphoma and bortezomib (Velcade) for multiple myeloma, in spite of their extensive availability.

  • Rituximab.  // Reactions Weekly;6/7/2008, Issue 1205, p25 

    The article describes the case of an 84-year-old man who developed acute thrombocytopenia following the administration of rituximab as part of his treatment regimen for mantle cell lymphoma. The patient's platelet count decreased, as well as his white blood cell (WBC) count. He also developed...

  • R-BAC shows promise in mantle cell lymphoma.  // Hem/Onc Today;4/25/2013, Vol. 14 Issue 8, p15 

    The article discusses the results of a study which showed that a therapy combining cytarabine, bendamustine and rituximab is linked to strong response-related outcomes in mantle cell lymphoma.

  • Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma. Deconinck, Eric; Miadi-Fargier, Houda; Le Pen, Claude; Brice, Pauline // PharmacoEconomics;2010, Vol. 28 Issue 1, p35 

    Background: Rituximab maintenance therapy was shown to significantly extend overall survival (OS) and progression-free survival (PFS) in relapsed/ refractory follicular lymphoma (FL) in the pivotal EORTC 20981 trial. Objective: To assess the long-term costs and cost effectiveness of rituximab...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics